A landmark trial said do not bridge anticoagulation around surgery. Then clinicians actually read it, and the patients on the wards were almost never in the study. Three internal medicine physicians, Benjamin Geisler, Jeffrey Greenwald, and Kathy May Tran, edit a book on the fifty studies every hospitalist should know. They walk through the DOSE trial, the BRIDGE misread, and what changes when AI can surface guidelines in seconds but cannot read your patient.

⏱️ Chapters:
0:00 Introduction
0:50 Why a diuretic drip may not beat a bolus
4:35 The case at the bedside that the DOSE trial actually changes
6:48 The studies that did not make the cut for the book
9:08 What residents demand now that we did not ask before
11:00 From biblically told to evidence based
13:29 The headline that misread the BRIDGE trial
15:55 Three challenges hospitalist EBM is about to face
16:39 Will AI make EBM literacy more or less important
17:21 Who was not in the trial
18:06 Take home messages

About this episode:
Three hospitalist editors of 50 Studies Every Hospitalist Should Know join Kevin to argue that the most dangerous moment in evidence-based medicine is the headline. Jeffrey Greenwald opens with the DOSE trial and its quiet finding that a continuous furosemide drip does not beat intermittent boluses, which means the reflex to escalate refractory heart failure patients onto a drip is often unfounded. Kathy May Tran traces how training has shifted from learning what to do to asking why for this specific patient, a cultural change she sees in her own residents on the wards. Benjamin Geisler explains how the editors selected only studies that have stood the test of time, and why studies under five or ten years old were left out. Greenwald then walks through the BRIDGE trial as the cautionary example, where a do-not-bridge headline got splashed across the press while only ten to twelve percent of enrolled patients were the high-risk surgical patients hospitalists actually manage. They close on the AI question: when guidelines are one prompt away, EBM literacy may matter more, not less, because someone still has to know who was not in the trial.

Tune into our episode "2026 Cholesterol Guidelines: LDL goals, lipoprotein(a), and coronary calcium scoring," brought to you by Novartis Pharmaceuticals Corporation.

For the first time in eight years, LDL cholesterol goals have changed, and preventive cardiologist Seth Baum says the new guidelines are a long-overdue course correction. He breaks down the new LDL targets for your highest-risk patients, why the LDL hypothesis should be retired in favor of the LDL fact, why lipoprotein(a) screening finally belongs in every patient's workup, what a coronary calcium score over 300 really means for how aggressively you treat, and how to talk to statin-skeptical patients without losing their trust. Listen now at KevinMD.com/cholesterol.

VISIT SPONSOR → https://kevinmd.com/cholesterol

🤝 Partner with me on the KevinMD platform:
With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Let's work together to tell your story.

➡️ PARTNER WITH KEVINMD: https://kevinmd.com/influencer
➡️ SUBSCRIBE TO THE PODCAST: https://www.kevinmd.com/podcast
➡️ RECOMMENDED BY KEVINMD: https://www.kevinmd.com/recommended

#HospitalMedicine #EvidenceBasedMedicine #InternalMedicine